Cargando…
Fewer tumour-specific PD-1(+)CD8(+) TILs in high-risk “Infiltrating” HPV(−) HNSCC
BACKGROUND: The prognosis of HPV(-) HNSCC was worse than that of HPV(+) HNSCC. Analysis of tumours and tumour-infiltrating lymphocytes (TILs) may provide insight into the progression of HPV(−) HNSCC. METHODS: The tumour and TIL phenotypic characteristics of 134 HNSCC specimens (HPV(−) tumours were c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492364/ https://www.ncbi.nlm.nih.gov/pubmed/32616847 http://dx.doi.org/10.1038/s41416-020-0966-8 |
Sumario: | BACKGROUND: The prognosis of HPV(-) HNSCC was worse than that of HPV(+) HNSCC. Analysis of tumours and tumour-infiltrating lymphocytes (TILs) may provide insight into the progression of HPV(−) HNSCC. METHODS: The tumour and TIL phenotypic characteristics of 134 HNSCC specimens (HPV(−) tumours were classified into “Infiltrating” and “Pushing” subtypes based on their different tumour nest configuration and prognosis) were retrospectively analysed. HNSCC data from the Cancer Genome Atlas (n = 263) were analysed for CD8α, HPV and overall survival (OS). A murine HNSCC model was used to verify the antitumour role of PD-1(+)CD8(+) TILs. RESULTS: The “Infiltrating” HPV(−) subtype showed shorter OS than the “Pushing” subtype. Moreover, there is a tendency from “Pushing” to “Infiltrating” subtype from the primary to the recurrent lesion. Different from total CD8(+) TILs, tumour-specific PD-1(+)CD8(+) TILs were fewer in invasive margin (IM) of “Infiltrating” HPV(−) tumours. PD-1(+)CD8(+) TILs recognised autologous HNSCC cells and showed stronger inhibition of tumour growth in a murine HNSCC model resistant to PD-1 blockade. CONCLUSIONS: Coevolution of HPV(−) HNSCC and TILs is characterised by an “Infiltrating” phenotype and less tumour-specific PD-1(+)CD8(+) TILs, which may provide a framework for further translational studies and patient stratification. |
---|